scispace - formally typeset
D

Donatella Coradduzza

Researcher at University of Sassari

Publications -  18
Citations -  95

Donatella Coradduzza is an academic researcher from University of Sassari. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 4 publications receiving 11 citations.

Papers
More filters
Journal ArticleDOI

Nanomaterials in Skin Regeneration and Rejuvenation

TL;DR: In this article, the authors summarize the recent nanotechnological approaches to maintain and replace skin homeostasis, with particular attention to nanomaterials applications on wound healing, regeneration and rejuvenation of skin tissue.
Journal ArticleDOI

Gold nanoparticles and cancer: Detection, diagnosis and therapy.

TL;DR: In this paper, the authors report the latest findings on AuNPs research addressing all their functions as theranostic agents, including their potential action is so appealing and the results so impressive that an outstanding number of papers are being published every year, with the consequence that any review on this topic becomes obsolete within a few months.
Journal ArticleDOI

Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer

TL;DR: The role of miRNAs-145, 148, and 185 and their correlation with stem cells in prostate cancer pathogenesis and in PCSC stemness regulation is focused on.
Journal ArticleDOI

A preliminary study procedure for detection of polyamines in plasma samples as a potential diagnostic tool in prostate cancer.

TL;DR: The method developed provides rapid, easy and robust identification and measurement of a wide range of polyamines, and some of their metabolites that can be evaluated as biomarkers to predict the clinical features of prostate cancer patients, avoiding invasive diagnostic procedures.
Journal ArticleDOI

Plasma Polyamine Biomarker Panels: Agmatine in Support of Prostate Cancer Diagnosis

TL;DR: Statistical analysis models revealed good discrimination using polyamine levels to distinguish the three classes of patients with prostate cancer, which could represent a future tool able to discriminate patients belonging to the three different clinical groups.